Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: Comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase

Human Gene Therapy

Volumn 7, Issue 18, 1996, Pages 2235-2245

  Rogers, Robert P ^a   Ge, Ji Qian ^b   Holley Guthrie, Elizabeth ^b   Hoganson, Diana K ^c   Comstock, Kenine E ^c   Olsen, John C ^c   Kenney, Shannon ^b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; PRODRUG; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL KILLING; COMPARATIVE STUDY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; ESCHERICHIA COLI; FEMALE; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOMA; NONHUMAN; RETROVIRUS; SCID MOUSE; SUICIDE GENE; TARGET CELL; TUMOR REGRESSION; VIRUS CARCINOGENESIS;

ANIMALIA; ESCHERICHIA COLI; HERPES; HUMAN HERPESVIRUS 4; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0030467588     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.18-2235     Document Type: Article

References (40)

1. ADAM, M.A., RAMESH, N., MILLER, A.D., and OSBORNE, W.R. (1991). Internal initiation of translation in retroviral vectors carrying picornavirus 5′ nontranslated regions. J. Virol. 65, 4985-4990.
2. ARNER, E.S.J., SPASOLOULOTSKAJA, T., and ERIKSSON, S. (1992). Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem. Biophys. Res. Commun. 188, 712-718.
3. AUSTIN, E.A., and HUBER, B.E. (1993). A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43, 380-387.
4. BECK, C., CAYEUX, S., LUPTON, S.D., DORKEN, B., and BLANKENSTEIN, T. (1995). The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum. Gene Ther. 6, 1525-1530.
5. BENNETT, J.E. (1990). Antifungal agents. In Principles and Practice of Infectious Diseases, 3rd ed. G.L. Mandell, R.G. Douglas, J.E. Bennett, eds. (Churchill Livingstone, New York) pp. 361-370.
6. BORDIGNON, C., BONINI, C., VERZELETTI, S., NOBILI, N., MAGGIONI, D., TRAVERSARI, C., GIAVAZZI, R., SERVIDA, P., ZAPPONE, E., BENAZZI, E., BERNARDI, M., PORTA, F., FERRARI, G., MAVILIO, F., ROSSINI, S., BLAESE, M., and CANDOTTI, F. (1995). Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum. Gene Ther. 6, 813-819.
7. CHEN, C.-Y., CHANG, Y.-N., RYAN, P., LINSCOTT, M., MCGARRITY, G.J., and CHIANG, Y.L. (1995). Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect." Hum. Gene Ther. 6, 1467-1476.
8. COLOMBO, B.M., BENEDETTI, S., OTTOLENGHI, S., MORA, M., POLLO, B., POLI, G., and FINOCCHIARO, G. (1995). The "bystander effect": Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. 6, 763-772.
9. COMSTOCK, K.E., WATSON, N.F., and OLSEN, J.C. (1996). Design of retroviral expression vectors. In Methods in Molecular Biology: Recombinant Gene Expression. R. Tuan, ed. (Humana Press, Totowa, NJ) in press.
10. CONNERS, T. A. (1995). The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2, 702-709.
11. COUTURE, L.A., MULLEN, C.A., and MORGAN, R.A. (1994). Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type specific gene expression. Hum. Gene Ther. 5, 667-677.
12. CULVER, K.W., and VAN GILDER, J. (1994). Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 343-379.
13. CURIEL, T.J., COOK, D.R., BOGEDAIN, C., JILG, W., HARRISON, G.S., COTTEN, M., CURIEL, D.T., and WAGNER, E. (1994). Efficient foreign gene expression in Epstein-Barr virus-transformed human B-cells. Virology 198, 577-585.
14. DOMIN, B.A., MAHONY, W.B., and ZIMMERMAN, T.P. (1993). Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem. Pharmacol. 46, 503-510.
15. ERNBERG, I., and ALTIOK, E. (1989). The role of Epstein-Barr virus in lymphomas of HIV carriers. APMIS 97 (Suppl. 8), 58-61.
16. FIXMAN, E., HAYWARD, G., and HAYWARD, S.D. (1992). trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J. Virol. 66, 5030-5039.
17. FREEMAN, S.M., ABOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
18. HAMILTON-DUTOIT, S.J., RAPHAEL, M., AUDOUIN, J., DIEBOLD, J., LISSE, I., PEDERSEN, C., OKSENHENDLER, E., MARELLE, L., and PALLESEN, G. (1993). In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: Correlation with tumor morphology and primary site. Blood 82, 619-624.
19. HAMMERSCHMIDT, W., and SUGDEN, B. (1988). Identification and characterization of oriLyt, a lytic origin of replication of Epstein-Barr virus. Cell 55, 427-433.
20. HAYDEN, F.G., and DOUGLAS, R.G. (1990). Antiviral agents. In Principles and Practice of Infectious Diseases, 3rd ed. G.L. Mandell, R.G. Douglas, and J.E. Bennett, eds. (Churchill Livingstone, New York) pp. 371-393.
21. HE, M., WILDE, A., and KADERBHAI, M.A. (1990). A simple single-step procedure for small-scale preparation of Escherichia coli plasmids. Nucleic Acids Res. 18, 1660.
22. HIRSCHOWITZ, E.A., OHWADA, A., PASCAL, W.R., RUSSI, T.J., and CRYSTAL, R.G. (1995). In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytostine. Hum. Gene Ther. 6, 1055-1063.
23. HOGANSON, D.K., BATRA, R.K., OLSEN, J.C., and BOUCHER, R.C. (1996). Combination of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 56, 1315-1323.
24. HUBER, B.E., AUSTIN, E.A., RICHARDS, C.A., DAVIS, S.T., and GOOD, S.S. (1994). Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91, 8302-8306.
25. JUDDE, J.-G., SPANGLER, G., MAGRATH, I., and BHATIA, K. (1996). Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum. Gene Ther. 7, 647-653.
26. KUN, L.E., GAJJAR, A., MUHLBAUER, M., HEIDEMAN, R.L., SANFORD, R., BRENNER, M., WALTER, A., LANGSTON, J., JENKINS, J., and FACCHINI, S. (1995). Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum. Gene Ther. 6, 1231-1255.
27. MACMAHON, E.M.E., GLASS, J.D., HAYWARD, S.D., MANN, R.B., BECKER, P.S., CHARACHE, P., MCARTHUR, J.C., and AMBINDER, R.F. (1991). Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338, 969-973.
28. MATTHEWS, T., and BOEHME, R. (1988). Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10, S490-S494.
29. MEEKER, T.C., SHIRAMIZU, B., KAPLAN, L., HERNDIER, B., SANCHEZ, H., GRIMALDI, J.C., BAUMGARTNER, J., RACHLIN, J., FEIGAL, E., ROSENBLUM, M., and MCGRATH, M.S. (1991). Evidence for molecular subtypes of HIV-associated lymphoma: Division into peripheral monoclonal, polyclonal, and central nervous system lymphoma. AIDS 5, 669-674.
30. MILLER, A.D., and BUTTIMORE, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6, 2895-2902.
31. OLSEN, J.C., and SECHELSKI, J. (1995). Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum. Gene Ther. 6, 1195-1202.
32. REISSMAN, D., YATES, J., and SUGDEN, B. (1985). A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol. Cell. Biol. 5, 1822-1932.
33. RICHARDS, C.A., AUSTIN, E.A., and HUBER, B.E. (1995). Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6, 881-893.
34. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13, 3321-3328.
35. THOMAS, J.A., ALLDAY, M.J., and CRAWFORD, D.H. (1991). Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res. 57, 329-380.
36. TIBERGHIEN, P. (1994). Use of suicide genes in gene therapy. J. Leuk. Biol. 56, 203-209.
37. TIBERGHIEN, P., REYNOLDS, C.W., KELLER, J., SPENCE, S., DESCHASEAUX, M., CERTOUX, J.-M., CONTASSOT, E., MURPHY, W.J., LYONS, R., CHIANG, Y., HERVE, P., LONGO, D.L., and RUSCETTI, F.W. (1994). Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation. Blood 84, 1333-1341.
38. TRINH, Q.T., AUSTIN, E.A., MURRAY, D.M., KNICK, V.C., and HUBER, B.E. (1995). Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 55, 4808-4812.
39. WENNERBERG, J., KJELLEN, E., LYBAK, S., RYDELL, R., and PERO, R. (1993). Biochemical modulation of chemotherapy and radiotherapy in head and neck cancer. Anticancer Res. 13, 2501-2506.
40. WU, J.K., CANO, W.G., MEYLAERTS, S.A.G., QI, P., VRIONIS, F., and CHERINGTON, V. (1994). Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35, 1094-1103.